PMD Device Solutions Valuation
Is PMDS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PMDS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PMDS (SEK1.3) is trading below our estimate of fair value (SEK61.56)
Significantly Below Fair Value: PMDS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PMDS?
Key metric: As PMDS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PMDS's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | SEK 39.90m |
| Market Cap | SEK 33.73m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | -2.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PMDS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.2x | ||
EXPRS2 ExpreS2ion Biotech Holding | 5.7x | 0.3% | SEK 45.1m |
GEAN Genetic Analysis | 1.5x | n/a | NOK 29.2m |
QUIA Quia Pharma | 13.1x | n/a | SEK 65.6m |
COMBI CombiGene | 16.5x | n/a | SEK 51.9m |
PMDS PMD Device Solutions | 0.8x | 62.0% | SEK 33.7m |
Price-To-Sales vs Peers: PMDS is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (9.2x).
Price to Sales Ratio vs Industry
How does PMDS's PS Ratio compare vs other companies in the SE Biotechs Industry?
| 6 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 12.2x | 17.7% | |
PMDS PMD Device Solutions | 0.8x | 62.0% | US$3.07m |
XBRANE Xbrane Biopharma | 1.5x | 61.1% | US$27.20m |
SPRINT Sprint Bioscience | 1.7x | 27.6% | US$9.38m |
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 12.2x | 49.2% | |
PMDS PMD Device Solutions | 0.8x | n/a | US$3.07m |
Price-To-Sales vs Industry: PMDS is good value based on its Price-To-Sales Ratio (0.8x) compared to the Swedish Biotechs industry average (11.8x).
Price to Sales Ratio vs Fair Ratio
What is PMDS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 10.5x |
Price-To-Sales vs Fair Ratio: PMDS is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Swedish Orphan Biovitrum
SEK 103.1b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 300.20
7D
-8.5%
1Y
24.2%
Corline Biomedical
SEK 139.3m
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
CLBIO
SEK 6.48
7D
-7.7%
1Y
-44.1%
Camurus
SEK 32.1b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
CAMX
SEK 546.00
7D
-12.2%
1Y
22.4%